H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cardiff Oncology (CRDF) to $13 from $14 and keeps a Buy rating on the shares. The firm says the initial CRDF-004 trial readout us expected by end of 2024.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Cardiff Oncology price target lowered to $13 from $14 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App